Natural killer T (NKT) cells comprise a specialized subset of T lymphocytes that express cell surface markers characteristic of NK cells. The ability of these cells to produce cytokines, activate cells of both the innate and adaptive immune responses, and recognize antigen in the context of CD1d molecules strongly suggest that NKT cells play a pivotal role in anti-tumor immunity. However, anti-tumor effects mediated by these cells may be compromised because cancer patients have a reduction in both NKT cell number and function. Therefore, we hypothesize that adoptive transfer of effector NKT cells will be an effective therapeutic strategy to enhance cancer immunotherapy. Our lab has previously developed MHC-lg and CD1d-lg-based artificial Antigen Presenting Cells (aAPC), which can facilitate the induction and expansion of primary T and NKT cells. In this proposal, we will further modify this CD1d-lg based aAPC to stimulate and analyze different NKT cell subsets in vitro. In addition we will evaluate the in vivo anti-tumor activity of the different NKT cell subsets in a human melanoma/SCID model. Collectively, these studies provide a novel approach to study the in vitro expansion as well as the in vitro and in vivo function of NKT cell subsets for potential use in adoptive cancer immunotherapy is presented. The information gained in the proposed studies will serve to help understand and design NKT cell based approaches to enhance current immunotherapeutic treatment strategies for cancer. A major goal in cancer immunotherapy is to generate an effective anti-tumor immune response. This application represents a novel approach using artificial Antigen Presenting Cells, aAPC, to study activation and expansion of NKT cells to enhance the efficiency of cancer immunotherapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Scientist Development Award - Research & Training (K01)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ojeifo, John O
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
Schools of Medicine
United States
Zip Code
Tiper, Irina V; Temkin, Sarah M; Spiegel, Sarah et al. (2016) VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. Clin Cancer Res 22:4249-58
Sun, Wenji; Wang, Yi; East, James E et al. (2015) Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional. Cytokine 72:48-57
Subrahmanyam, Priyanka B; Carey, Gregory B; Webb, Tonya J (2014) Bcl-xL regulates CD1d-mediated antigen presentation to NKT cells by altering CD1d trafficking through the endocytic pathway. J Immunol 193:2096-105
Li, Junxin; Sun, Wenji; Subrahmanyam, Priyanka B et al. (2014) NKT Cell Responses to B Cell Lymphoma. Med Sci (Basel) 2:82-97
East, James E; Kennedy, Andrew J; Webb, Tonya J (2014) Raising the roof: the preferential pharmacological stimulation of Th1 and th2 responses mediated by NKT cells. Med Res Rev 34:45-76
Sohn, Silke; Tiper, Irina; Japp, Emily et al. (2014) Development of a qPCR method to rapidly assess the function of NKT cells. J Immunol Methods 407:82-9
Kimball, Amy S; Webb, Tonya J (2013) The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma. Mol Cell Pharmacol 5:27-38
Li, Xiangming; Tsuji, Moriya; Schneck, Jonathan et al. (2013) Generation of Human iNKT Cell Lines. Bio Protoc 3:
Li, Xiangming; Tsuji, Moriya; Schneck, Jonathan et al. (2013) Generation of Mouse iNKT Cell Lines. Bio Protoc 3:
Subrahmanyam, Priyanka; Webb, Tonya J (2012) Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants. Front Biol (Beijing) 7:436-444

Showing the most recent 10 out of 16 publications